Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 23

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 23
---
 seventy-five percent of the market value of the related AbbVie common stock at year end.

| (2) | The amounts in this column represent the aggregate grant date fair value of the restricted stock unit awards granted during 2024, determined in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 718. AbbVie determines the grant date fair value of the |

2025 Proxy Statement |29

| ​                     | ​ |
| DIRECTOR COMPENSATION | ​ |

| awards by multiplying the number of units granted by the average of the high and low market prices of one share of AbbVie common stock on the award grant date. |

In addition to the fees described in footnote (1), each non-employee director elected to or serving on the Board of Directors on the day of the 2024 annual stockholder meeting received under the AbbVie Amended and Restated 2013 Incentive Stock Program vested restricted stock units with a target grant date value of $215,000. In 2024, this equated to 1,322 restricted stock units (after rounding the award down to the nearest whole unit), with a reportable value of $214,818. The non-employee directors receive cash payments equal to the dividends paid on the shares covered by the units at the same rate as other stockholders, but do not otherwise have access to the restricted stock units during their Board service. Upon termination or retirement from the Board, death, or a change in control of the company, a non-employee director will receive one common share for each restricted stock unit outstanding. The following AbbVie restricted stock units were outstanding as of December 31, 2024: R. Alpern, 34,314; R. Austin, 25,755; W. Burnside, 25,755; J. Davis, 1,322; T. Freyman, 8,207; B. Hart, 18,269; M. Meyer, 15,295; S. Quaggin, 1,322; E. Rapp, 25,755; R. Roberts, 12,525; G. Tilton, 25,755; and F. Waddell, 25,755.

| (3) | No AbbVie stock options were outstanding as of December 31, 2024. |

| (4) | The totals in this column include reportable interest credited